Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Invivyd
IVVD
Invivyd
Regulatory Risks And Competition Will Impede Gains But Yield Promise
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
22 Aug 25
Updated
22 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$3.00
82.7% undervalued
intrinsic discount
22 Aug
US$0.52
Loading
1Y
-48.5%
7D
-26.4%
Author's Valuation
US$3.0
82.7% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$3.0
82.7% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-280m
341m
2020
2021
2022
2023
2024
2025
2026
2027
2028
Revenue US$341.4m
Earnings US$25.0m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
38.03%
Biotech revenue growth rate
11.77%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$25.03m
Earnings '28
x
17.66x
PE Ratio '28
=
US$441.90m
Market Cap '28
US$441.90m
Market Cap '28
/
121.74m
No. shares '28
=
US$3.63
Share Price '28
US$3.63
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$2.98
Fair Value '25
